You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 -- 638 2022-04-07 04:31:03 |
2 revised + 1926 word(s) 2564 2022-04-07 07:51:48 | |
3 Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan Meta information modification 2564 2022-04-07 08:19:24 | |
4 revised + 7 word(s) 2571 2022-04-07 08:38:13 | |
5 revised Meta information modification 2571 2022-04-07 08:38:40 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Hamada, Y.; Ebihara, F.; Kato, H.; Maruyama, T.; Kimura, T. Importance and Reality of TDM for Antibiotics. Encyclopedia. Available online: https://encyclopedia.pub/entry/21438 (accessed on 17 July 2025).
Hamada Y, Ebihara F, Kato H, Maruyama T, Kimura T. Importance and Reality of TDM for Antibiotics. Encyclopedia. Available at: https://encyclopedia.pub/entry/21438. Accessed July 17, 2025.
Hamada, Yukihiro, Fumiya Ebihara, Hideo Kato, Takumi Maruyama, Toshimi Kimura. "Importance and Reality of TDM for Antibiotics" Encyclopedia, https://encyclopedia.pub/entry/21438 (accessed July 17, 2025).
Hamada, Y., Ebihara, F., Kato, H., Maruyama, T., & Kimura, T. (2022, April 07). Importance and Reality of TDM for Antibiotics. In Encyclopedia. https://encyclopedia.pub/entry/21438
Hamada, Yukihiro, et al. "Importance and Reality of TDM for Antibiotics." Encyclopedia. Web. 07 April, 2022.
Importance and Reality of TDM for Antibiotics
Edit

Under the Japanese health insurance system, medicines undergoing therapeutic drug monitoring (TDM) can be billed for medical fees if they meet the specified requirements. In Japan, TDM of vancomycin, teicoplanin, aminoglycosides, and voriconazole, which are used for the treatment of infectious diseases, is common practice. This means the levels of antibiotics are measured in-house using chromatography or other methods. In some facilities, the blood and/or tissue concentrations of other non-TDM drugs are measured by HPLC and are applied to treatment, which is necessary for personalized medicine.

HPLC TDM ceftriaxone daptomycin

1. Characteristics of Ceftriaxone (CTRX) and Significance of Therapeutic Drug Monitoring (TDM)

Ceftriaxone (CTRX) is a third-generation cephalosporin that has a broad antibacterial spectrum, good tissue migration, and a longer half-life than other cephalosporins, allowing for once-daily administration. CTRX has been used for a variety of indications and has many opportunities for use [1]. In addition, dose adjustment is not necessary for patients with impaired renal function [2]. Patel et al. reported that adjusting the dosage regimen of ceftriaxone for patients with impaired renal function should not be necessary when the daily dosage is 2 g or lower [3]. Antibiotic-associated encephalopathy (AAE) is a known side effect of cephalosporins. AAE is classified into three major categories: type I for cephalosporins and penicillins, type II for quinolones and macrolides, and type III for metronidazole; type I is said to be free of epileptic waves [4]. In particular, there have been many reports on AAE with cefepime (CFPM), a fourth-generation cephalosporin drug, including reports on the intoxication zone of blood levels responsible for AAE [5][6][7]. There are also scattered reports of AAE caused by CTRX, and according to an adverse drug reaction database study in France, the serious CNS adverse effects caused by CTRX and CFPM were reported to be similar [8]. AAE with CTRX has been reported more frequently in the elderly and patients with chronic kidney disease and is more likely to occur when high doses are given and blood and cerebrospinal fluid (CSF) concentrations are high [9][10][11].
In a recent report, Lacroix et al. [12] used the French pharmacovigilance database to analyze records of CNS adverse events due to CTRX that were recorded as occurring in 1995–2017. A total of 152 serious adverse drug reactions (ADRs) were analyzed: 112 resulted in hospitalization or prolonged hospitalization (73.7%), 12 resulted in death (7.9%), and 16 were life-threatening. The median age was 74.5 years, and the median rate of creatinine clearance (CLcr) was 35 mL/min. The median time of onset was 4 days; the mean daily dose was 1.7 g, with three patients receiving doses exceeding the maximum recommended dose; and plasma ceftriaxone levels were recorded in 19 patients (12.5%), with eight patients exceeding the threshold for toxicity (>100 μg/mL). In addition, electroencephalography performed on 50 patients (32.9%) showed abnormalities in 37 (74%).
Although the frequency of CTRX-related encephalopathy in Japan is not clear, it has been reported that the sales volume of third-generation cephalosporins is about six times higher than that of fourth-generation cephalosporins [13], and caution is required.

2. Report on the Measurement of Blood Levels and Cerebrospinal Fluid (CSF)  of CTRX in Japan

In Japan, researchers searched for clinically applied studies on CTRX that are not generally clinically measured. As a result, researchers present reports on the measurement of CTRX concentrations in cerebrospinal fluid by HPLC−UV in Japan.
Kotani et al. [14] measured CTRX concentrations in CSF samples collected from peritoneal dialysis patients diagnosed with CTRX-induced encephalopathy (CIE) using an HPLC–UV system to investigate whether high CTRX concentrations in CSF are associated with CIE. Their study used an octadecyl silica (ODS) column, methanol, and a mobile phase of mixed solution (25:75, v/v) in 10 mM phosphate to accurately analyze the CSF samples from CIE patients; the detection wavelength was 280 nm. Based on the current HPLC–UV capability, a linear range of 0.1–100 μg/mL (r = 0.999) was obtained. In a recovery study using a blank sample of human CSF and a control serum supplemented with CTRX, the recovery of CTRX was ≥95.3%, and the RSD was <5.8% (n = 3). CTRX in CSF and serum obtained from a patient diagnosed with CIE was measured using the developed HPLC–UV system. The concentration of CTRX in CSF and serum was 2.61 and 37.35 μg/mL, respectively. Researchers simulated the serum and CSF concentrations of CTRX using simulation software developed by Oda (Figure 1) [15].
Figure 1. Simulation of blood concentration and human cerebrospinal fluid after ceftriaxone administration [14]. Researchers completed the simulation ourselves using researchers' results. The solid line shows changes in blood concentration after ceftriaxone administration, and the dotted line shows changes in cerebrospinal fluid.
Suzuki et al. [16] reported the case of a patient with renal failure who experienced encephalopathy induced by CTRX. An 86-year-old woman undergoing maintenance hemodialysis was treated with CTRX for Helicobacter cinaedi bacteremia, and her mental status worsened during antibiotic administration. During the period when CTRX was administered at 2 g/day, the measured plasma and CSF CTRX concentrations were high (>100 and 10.2 μg/mL, respectively). The patient reported that her mental status improved after the antibiotic treatment was stopped. Table 1 shows the PubMed search results for reports that measured blood and CSF concentrations of CTRX, DAP, LZD, and TZD in Japan.
Table 1. Summary of Japanese reports on serum and CSF concentrations of CTRX, DAP, LZD, and TZD [14][16][17][18][19][20][21][22][23][24][25][26][27][28][29].
Drug Characteristics Objective Renal Function Dose Measurement System Measurement Accuracy Blood Concentration CSF Concentration Ref.
CTRX Age: 75 Sex: female Development of HPLC method for accurate, precise, and selective determination of CTRX and its clinical application peritoneal dialysis 2 g/day HPLC-UV -Chromatographic peak heights of CTRX: 0.1–100 μg/mL (r = 0.999)
-Detection limit of CTRX: 35 ng/mL
-Repeatability (n = 6) of the chromatographic peak height for 4.0 μg/mL CTRX: 0.38% RSD.-Recovery rates of CTRX: >95.3%, and these RSDs were <5.8%
37.35 μg/mL 2.61 μg/mL [14]
Age: 86 Sex: female Report of encephalopathy associated with high levels of ceftriaxone in plasma and cerebrospinal fluid, investigation of the causal relationship between ceftriaxone administration and the development of encephalopathy hemodialysis 2 g/day HPLC nd >100 μg/mL 10.2 μg/mL [16]
Population: n = 43 patients Sex: male
median age: 51.7 years (IQR 33.3–67.1)
median BMI: 24.7 kg/m2 (IQR 22.4–27.7 kg/m2)
Determining the role of transporter genetic variation and blood-brain barrier permeability in predicting ceftriaxone exposure in the central nervous system estimated creatinine
clearance < 30 mL/min
2 g twice a day HPLC -Detection limits: 0.24 mg/L in plasma and 0.5 mg/L in CSF
-Accuracy: 5.2% for plasma, 7.2% for CSF
-Intra- and inter-day coefficients of variation (CV%): 3.6% and 4.5% for plasma samples, and 7.2%, 7.8%, and 10.3% for CSF samples
-Recovery rate: 86% (CV% = 3) for CSF samples and 82% (CV% = 8) for plasma samples.
Median Cmax: 157,193.00 ng/mL
(IQR 105,164.0–184,852.0 ng/mL)
Median Cmax: 3512.0 ng/mL
(IQR 2134.0–6193.0 ng/mL)
[17]
Population: n = 16 patients Evaluation of tolerability and pharmacokinetic parameters of high-dose ceftriaxone in adult patients treated for central nervous system infections: pharmacological data from two French cohorts nd 6.5 g/day (range 4–9 g) 97.5 mg/kg (range 77–131 mg/kg) HPLC nd Median total plasma: 69.3 mg/L (range 21.6–201.3 mg/L; n =14) Median unbound plasma: 7.95 mg/L (range 0.8–43.7 mg/L; n = 8) Median: 13.3 mg/L (range 0.9–91.2 mg/L) [18]
Population: n = 7 patients Investigation of the pharmacokinetics ofboth antibiotics in patients with non- inflammatory obstructive hydrocephalus undergoing external ventricular surgery treated with cefotaxime or ceftriaxone for extracerebral infections Scr < 1.5 mg/dL 2 g single dose 30 min HPLC-UV -Quantification limits of ceftriaxone; 0.8 mg/L in serum and 0.08 mg/L in CSF.
-Interday coefficients of variation; 2.0% 249.6; n = 6) at 99.7 and 6.8% at 1.55 mg/L inserum and 3.3% at 16.2 and 6.4% at 0.16 mg/L in CSF (n = 6).
Cmax: 172.2–271.7 mg/L (median = 249.6; n = 6) Cmax: 0.18–1.04 mg/L (median = 0.43; n = 5), confirmed 1–16 h after injection (median = 12 h; n = 5). [19]
DAP Population:16 patients (8 males and 8 females)
Age: 70.0 ± 3.4 years
weight: 47.6 ± 5.0 kg
Investigate the optimal dosing regimen for daptomycin and determine the need and appropriateness of a high-dose regimen in terms of PK / PD parameters using Monte Carlo Simulation and TDM in a Japanese clinical setting CLcr 16.2–173.4 mL/min (n = 11)
hemodialysis (n = 5)
single doses (6 mg/kg, 8 mg/kg, 10 mg/kg, and 12 mg/kg) and dosing intervals (24 h and 48 h) HPLC-UV -Lowest limit of quantification: 0.78 μg/mL Cmin: 0.13–49.4 μg/mL
Cpeak: 34.2–130.0 μg/mL
nd [20]
Population: n = 20 patients Investigate associations between DAP Cmin and creatine phosphokinase elevation via logistic regression analysis (E/R analysis), and to analyze DAP PPK via adaptation of a one-compartment model in Japanese patients to determine optimal DAP doses for minimizing adverse effects and maximizing treatment success by E/R analysis. CLcr 22.4–213.8 mL/min, 2.8–8.6 mg/kg HPLC-UV -Lowest limit of quantitation: 1.0 μg/mL
-within-day and between-day coefficients of variation of <5.0%.
Cmin: 2.8–92.4 μg/mL
Cpeak: 30.4–76.7 μg/mL
nd [21]
Population: n = 15 patients Development of an assay method for the determination of total and free daptomycin in human plasma nd 4–8 mg/kg once over a 24-hour period. LC-MS/MS -Concentration ranges: 1.0–100 μg/mL in total daptomycin and 0.1–10 μg/mL in free daptomycin
- Limits of quantitation: 1.0 μg/mL(total daptomycin) and 0.1 μg/mL(free daptomycin)
-Recovery rate: total daptomycin measurements ranged from 106.1% and free daptomycin measurements ranged from 98.2%
The plasma concentration ranges of total and free daptomycin in 15 infected patients were 3.01–34.1 and 0.39–3.64 μg/mL nd [22]
Population: two patients admitted to intensive care unit (2 males)
Weight: 61.1 kg, 59.0 kg
Development of a new assay for measuring total and free concentrations of daptomycin in plasma with potential clinical applications CLcr 17.5 mL/min
CLcr 140.5 mL/min
-every 48 h of 350 mg
(CLcr < 30 mL/min)-once-daily dose of 350 mg (CLcr ≥ 30 mL/min)
UPLC-MS / MS -Concentration ranges: 0.5–200 μg/mL in total daptomycin and 0.04–40 μg/mL in free daptomycin-Recovery rate: approximately 100% of free daptomycin from ultrafiltration
-Limits of quantitation: 0.5 μg/mL (total daptomycin) and 0.04 μg/mL (free daptomycin)
-Recovery rate: total daptomycin measurements ranged from 57.1 to 67.4% and free daptomycin measurements ranged from 54.6 to 62.3%
-Patient with low renal function: Cmax of free drug: 2.85 µg/mL (Day 3), 4.2 µg/mL (Day 5)
Ctrough of free drug: 0.29 µg/mL (Day 3), 0.86 µg/mL (Day 5)
-Patient with normal renal function: Median unbound plasma:
Cmax of free drug: 2.69 µg/mL (Day 3), 2.77 µg/mL (Day 5)
Ctrough of free drug: 0.77 µg/mL (Day 3), 0.34 µg/mL (Day 5)
nd [23]
Population: n = 53 patients
Sex: Male (n = 33), female (n = 19)
Examine serum daptomycin levels, creatinine phosphokinase levels, and the incidence of other adverse effects CLcr ≥ 80 mL/min: n = 15
30 ≤ CLcr < 80 mL/min: n = 23
CLcr < 30 mL/min: n = 14
haemodialysis: n = 8
4.0 < dose ≤5.0 mg/kg: n = 7
5.0 < dose ≤6.0 mg/kg: n = 19
6.0 < dose ≤7.0 mg/kg: n = 17
≤7.0 mg/kg: n = 4
HPLC-PDA -Response at the lowest concentration (3.5 μg/mL) was significantly more than 5 times higher than that of the blank serum
-Interday coefficient of variation for the lowest and highest concentration (200 μg/mL) samples was within 15%.
Cmax: 172.2–271.7 mg/L (median = 249.6; n = 6) nd [24]
LZD Age: 78
Sex: male
weight: 48.2 kg
Treatment of mediastinitis with TDM of serum and wound exudate concentrations of linezolid in renal function impaired patients. Scr: 5.6 mg/dL
glomerular filtration rate: 8.6 mL/min/1.73 m2
600 mg every 24 h
After that, 300 mg every 24 h
HPLC -Lower limit: 0.1 μg/mL
-Intra/interday precision below 5.0%
Cmin: 11.5 μg/mL (Day 21)
Cmin: 5.5 μg/mL (Day 55)
nd [25]
Age: 77
Sex: female
weight: 55 kg
TDM was effective in preventing thrombocytopenia with linezolid: a case report CLcr 29.9 mL/min 600 mg twice a day
After that, 600 mg every 24 h
HPLC -Lower limit: 0.25 μg/mL
-Intra/interday precision below 5.0%
39.4 µg/mL (Day 9) nd [26]
Age: 79
Sex: female
weight: 58.5 kg
Successful combination therapy with linezolid and rifampicin with appropriate management of linezolid TDM in MRSA osteomyelitis: a case report Scr 0.4 mg/dL 600 mg twice a day
Thereafter, 300 mg twice a day
At the time rifampicin is combined, 600 mg twice a day
HPLC -Lower limit: 0.1 μg/mL
-Intra/interday precision below 5.0%
Cmin: 15.1 µg/mL (Day 5) Cmin: 13.9 µg/mL (Day 8)
As a result of combination therapy, Cmin was in the optimal range of 3.7 to 7.2 mg/mL.
nd [27]
TZD Population: n = 3 patients Development of an assay system for simultaneous quantification of plasma concentrations of LZD, DAP, and TZD and its clinical application CLcr 48.3–64.5 mL/min 200 mg once daily UPLC-MS/MS -TZD showed good linearity over wide ranges of 5–5000 ng/mL.
-The lower limited of quantification and three quality controls (QCs: low, medium and high) were less than 15% for both accu-racy and precision.
-Recovery rate of TZD: more than 84.8%
Cpeak and Cmin of TZD ranged from 1.87 to 4.92 μg/mL and from 0.09 to 0.78 μg/mL nd [28]
Population: n = 3 patients Development of an assay for simultaneous quantification of 12 antimicrobial agents commonly used in ICU and its clinical application CLcr 51.7–60.4 mL/min 200 mg once daily UHPLC-MS/MS -The concentration ranges of calibration curves for TZD was 0.01–5 μg/mL.
-The measured concentrations in blanks were less than 20% of the peak response of the lower limited of quantification and less than 5% for internal standard
The ranges of Cmin and Cpeak in patients with CLcr of 51.7–60.4 mL/min were 0.06–0.12 and 2.67–4.01 μg/mL nd [29]
LZD Age: 78
Sex: male
weight: 48.2 kg
Treatment of mediastinitis with TDM of serum and wound exudate concentrations of linezolid in renal function impaired patients. Scr: 5.6 mg/dL
glomerular filtration rate: 8.6 mL/min/1.73 m2
600 mg every 24 h
After that, 300 mg every 24 h
HPLC -Lower limit: 0.1 μg/mL
-Intra/interday precision below 5.0%
Cmin: 11.5 μg/mL (Day 21)
Cmin: 5.5 μg/mL (Day 55)
nd [25]
Age: 77
Sex: female
weight: 55 kg
TDM was effective in preventing thrombocytopenia with linezolid: a case report CLcr 29.9 mL/min 600 mg twice a day
After that, 600 mg every 24 h
HPLC -Lower limit: 0.25 μg/mL
-Intra/interday precision below 5.0%
39.4 µg/mL (Day 9) nd [26]
Age: 79
Sex: female
weight: 58.5 kg
Successful combination therapy with linezolid and rifampicin with appropriate management of linezolid TDM in MRSA osteomyelitis: a case report Scr 0.4 mg/dL 600 mg twice a day
Thereafter, 300 mg twice a day
At the time rifampicin is combined, 600 mg twice a day
HPLC -Lower limit: 0.1 μg/mL
-Intra/interday precision below 5.0%
Cmin: 15.1 µg/mL (Day 5)
Cmin: 13.9 µg/mL (Day 8)
As a result of combination therapy, Cmin was in the optimal range of 3.7 to 7.2 mg/mL.
nd [27]
TZD Population: n = 3 patients Development of an assay system for simultaneous quantification of plasma concentrations of LZD, DAP, and TZD and its clinical application CLcr 48.3–64.5 mL/min 200 mg once daily UPLC-MS/MS -TZD showed good linearity over wide ranges of 5–5000 ng/mL.
-The lower limited of quantification and three quality controls (QCs: low, medium and high) were less than 15% for both accu-racy and precision.
-Recovery rate of TZD: more than 84.8%
Cpeak and Cmin of TZD ranged from 1.87 to 4.92 μg/mL and from 0.09 to 0.78 μg/mL nd [28]
Population: n = 3 patients Development of an assay for simultaneous quantification of 12 antimicrobial agents commonly used in ICU and its clinical application CLcr 51.7–60.4 mL/min 200 mg once daily UHPLC-MS/MS -The concentration ranges of calibration curves for TZD was 0.01–5 μg/mL.
-The measured concentrations in blanks were less than 20% of the peak response of the lower limited of quantification and less than 5% for internal standard
The ranges of Cmin and Cpeak in patients with CLcr of 51.7–60.4 mL/min were 0.06–0.12 and 2.67–4.01 μg/mL nd [29]
HPLC:high performance liquid chromatography; HPLC-UV:high performance liquid chromatography with ultraviolet detection; Scr:serum creatinine; CSF: cerebrospinal fluid; IQR:interquartile range; RSD: relative standard deviation; nd: not described; LC-MS/MS:Liquid Chromatograph-tandem Mass Spectrometer; UPLC-MS/MS:ultra-performance liquid chromatography coupled to tandem mass spectrometry; HPLC-PDA:high-performance liquid chromatography equipped with photodiode array; CLcr:creatinine clearance; MRSA: methicillin resistant Staphylococcus aureus; UHPLC-MS/MS:ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.
In Japan, the measurement of the CTRX blood concentration is not covered by insurance and is limited to facilities with appropriate laboratory equipment. In practice, there is a time lag between collecting samples and obtaining blood concentration results, making it difficult to use them for differential diagnosis in real time. LC–MS systems can measure blood levels more accurately than HPLC systems, but are expensive and therefore impractical. In the future, it would be desirable to have a test system that can be used in general practice so that the CTRX blood concentration can be measured when AAE is suspected. These reports suggest that TDM of CTRX may be able to prevent the occurrence of AAE.

References

  1. Klein, N.C.; Cunha, B.A. Third-Generation Cephalosporins. Med. Clin. N. Am. 1995, 79, 705–719.
  2. Aronoff, G.R.; Bennett, W.M.; Berns, J.S.; Brier, M.E.; Kasbekar, N.; Mueller, B.A.; Pasko, D.A.; Smoyer, W.E. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed.; American College of Physicians: Philadelphia, PA, USA, 2007; p. 153.
  3. Patel, I.H.; Sugihara, J.G.; Weinfeld, R.E.; Wong, E.G.; Siemsen, A.W.; Berman, S.J. Ceftriaxone Pharmacokinetics in Patients with Various Degrees of Renal Impairment. Antimicrob. Agents Chemother. 1984, 25, 438–442.
  4. Bhattacharyya, S.; Darby, R.R.; Raibagkar, P.; Gonzalez Castro, L.N.; Berkowitz, A.L. Antibiotic-Associated Encephalopathy. Neurology 2016, 86, 963–971.
  5. Lamoth, F.; Buclin, T.; Pascual, A.; Vora, S.; Bolay, S.; Decosterd, L.A.; Calandra, T.; Marchetti, O. High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function. Antimicrob. Agents Chemother. 2010, 54, 4360–4367.
  6. Durand-Maugard, C.; Lemaire-Hurtel, A.-S.; Gras-Champel, V.; Hary, L.; Maizel, J.; Prud’homme-Bernardy, A.; Andréjak, C.; Andréjak, M. Blood and CSF Monitoring of Cefepime-Induced Neurotoxicity: Nine Case Reports. J. Antimicrob. Chemother. 2012, 67, 1297–1299.
  7. Rhodes, N.J.; Kuti, J.L.; Nicolau, D.P.; Neely, M.N.; Nicasio, A.M.; Scheetz, M.H. An Exploratory Analysis of the Ability of a Cefepime Trough Concentration Greater than 22 Mg/L to Predict Neurotoxicity. J. Infect. Chemother. 2016, 22, 78–83.
  8. Lacroix, C.; Kheloufi, F.; Montastruc, F.; Bennis, Y.; Pizzoglio, V.; Micallef, J. Serious Central Nervous System Side Effects of Cephalosporins: A National Analysis of Serious Reports Registered in the French Pharmacovigilance Database. J. Neurol. Sci. 2019, 398, 196–201.
  9. Kim, K.B.; Kim, S.M.; Park, W.; Kim, J.S.; Kwon, S.K.; Kim, H.-Y. Ceftiaxone-Induced Neurotoxicity: Case Report, Pharmacokinetic Considerations, and Literature Review. J. Korean Med. Sci. 2012, 27, 1120–1123.
  10. Yokoyama, Y.; Hosokawa, N.; Kudo, T.; Goda, H.; Ito, K.; Suzuki, M.; Funakoshi, R. Chorea-like Symptoms and High Blood Concentration of Ceftriaxone in a Patient Undergoing Hemodialysis: A Case Report. J. Infect. Chemother. 2020, 26, 285–288.
  11. Inoue, Y.; Doi, Y.; Arisato, T.; Sugioka, S.; Koga, K.; Nishioka, K.; Sugawara, A. Three Cases of Hemodialysis Patients Receiving High-Dose Ceftriaxone: Serum Concentrations and Its Neurotoxicity. Kidney Int. Rep. 2017, 2, 984–987.
  12. Lacroix, C.; Bera-Jonville, A.-P.; Montastruc, F.; Velly, L.; Micallef, J.; Guilhaumou, R. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics 2021, 10, 540.
  13. AMR Clinical Reference Center. Surveillance of Antibiotic Sales in Japan. Available online: https://amrcrc.ncgm.go.jp/surveillance/020/salestableDDD2017_2021.4.xlsx (accessed on 18 December 2021).
  14. Kotani, A.; Hirai, J.; Hamada, Y.; Fujita, J.; Hakamata, H. Determination of Ceftriaxone Concentration in Human Cerebrospinal Fluid by High-Performance Liquid Chromatography with UV Detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2019, 1124, 161–164.
  15. Oda, K. Development of Software for Antimicrobial PK/PD Simulation Incorporating Montecarlo Simulation Based on Microsoft®; Office Excel. Iryo Yakugaku 2011, 37, 335–344.
  16. Suzuki, S.; Naito, S.; Numasawa, Y.; Asada, M.; Shoji, N.; Zeniya, M.; Takahashi, D.; Sato, H.; Iimori, S.; Nomura, N.; et al. Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentrations in a Hemodialysis Patient. Intern. Med. 2019, 58, 1775–1779.
  17. Allegra, S.; Cardellino, C.S.; Fatiguso, G.; Cusato, J.; De Nicolò, A.; Avataneo, V.; Bonora, S.; D’Avolio, A.; Di Perri, G.; Calcagno, A. Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J. Clin. Pharmacol. 2018, 58, 1550–1556.
  18. Le Turnier, P.; Grégoire, M.; Garot, D.; Guimard, T.; Duval, X.; Bernard, L.; Boutoille, D.; Dailly, É.; Navas, D.; Asseray, N. CSF Concentration of Ceftriaxone Following High-Dose Administration: Pharmacological Data from Two French Cohorts. J. Antimicrob. Chemother. 2019, 74, 1753–1755.
  19. Nau, R.; Prange, H.W.; Muth, P.; Mahr, G.; Menck, S.; Kolenda, H.; Sörgel, F. Passage of Cefotaxime and Ceftriaxone into Cerebrospinal Fluid of Patients with Uninflamed Meninges. Antimicrob. Agents Chemother. 1993, 37, 1518–1524.
  20. Urakami, T.; Hamada, Y.; Oka, Y.; Okinaka, T.; Yamakuchi, H.; Magarifuchi, H.; Aoki, Y. Clinical Pharmacokinetic and Pharmacodynamic Analysis of Daptomycin and the Necessity of High-Dose Regimen in Japanese Adult Patients. J. Infect. Chemother. 2019, 25, 437–443.
  21. Yamada, T.; Ooi, Y.; Oda, K.; Shibata, Y.; Kawanishi, F.; Suzuki, K.; Nishihara, M.; Nakano, T.; Yoshida, M.; Uchida, T.; et al. Observational Study to Determine the Optimal Dose of Daptomycin Based on Pharmacokinetic/Pharmacodynamic Analysis. J. Infect. Chemother. 2020, 26, 379–384.
  22. Miyadera, Y.; Naito, T.; Yamada, T.; Kawakami, J. Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. Ther. Drug Monit. 2018, 40, 589–595.
  23. Tanaka, R.; Suzuki, Y.; Goto, K.; Yasuda, N.; Koga, H.; Kai, S.; Ohchi, Y.; Sato, Y.; Kitano, T.; Itoh, H. Development and Validation of Sensitive and Selective Quantification of Total and Free Daptomycin in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 2019, 165, 56–64.
  24. Ando, M.; Nishioka, H.; Nakasako, S.; Kuramoto, E.; Ikemura, M.; Kamei, H.; Sono, Y.; Sugioka, N.; Fukushima, S.; Hashida, T. Observational Retrospective Single-Centre Study in Japan to Assess the Clinical Significance of Serum Daptomycin Levels in Creatinine Phosphokinase Elevation. J. Clin. Pharm. Ther. 2020, 45, 290–297.
  25. Tsuji, Y.; Tashiro, M.; Ashizawa, N.; Ota, Y.; Obi, H.; Nagura, S.; Narukawa, M.; Fukahara, K.; Yoshimura, N.; To, H.; et al. Treatment of Mediastinitis Due to Methicillin-Resistant Staphylococcus Aureus in a Renal Dysfunction Patient Undergoing Adjustments to the Linezolid Dose. Intern. Med. 2015, 54, 235–239.
  26. Matsuda, S.; Kimura, R.; Izumi, K.; Noguchi, A.; Imazu, T.; Kugaya, Y.; Shimokawa, F.; Maeda, Y. Two Cases for Prevention of Linezolid-Induced Thrombocytopenia by Therapeutic Drug Monitoring. J. Jpn. Soc. Hosp. Pharm. 2019, 55, 423–427.
  27. Ashizawa, N.; Tsuji, Y.; Kawago, K.; Higashi, Y.; Tashiro, M.; Nogami, M.; Gejo, R.; Narukawa, M.; Kimura, T.; Yamamoto, Y. Successful Treatment of Methicillin-Resistant Staphylococcus Aureus Osteomyelitis with Combination Therapy Using Linezolid and Rifampicin under Therapeutic Drug Monitoring. J. Infect. Chemother. 2016, 22, 331–334.
  28. Tanaka, R.; Kai, M.; Goto, K.; Ohchi, Y.; Yasuda, N.; Tatsuta, R.; Kitano, T.; Itoh, H. High-Throughput and Wide-Range Simultaneous Determination of Linezolid, Daptomycin and Tedizolid in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 2021, 194, 113764.
  29. Kai, M.; Tanaka, R.; Suzuki, Y.; Goto, K.; Ohchi, Y.; Yasuda, N.; Tatsuta, R.; Kitano, T.; Itoh, H. Simultaneous Quantification of Plasma Levels of 12 Antimicrobial Agents Including Carbapenem, Anti-Methicillin-Resistant Staphylococcus Aureus Agent, Quinolone and Azole Used in Intensive Care Unit Using UHPLC-MS/MS Method. Clin. Biochem. 2021, 90, 40–49.
More
Upload a video for this entry
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , ,
View Times: 828
Revisions: 5 times (View History)
Update Date: 07 Apr 2022
1000/1000
Hot Most Recent
Academic Video Service